Showing posts with label Osphos. Show all posts
Showing posts with label Osphos. Show all posts

Monday, July 28, 2014

Navicular Syndrome: Does FDA Approval of Tildren and Osphos Change Anything?

equine distal limb hoof
From bone to zone: Focus on navicular-type lameness has evolved from concentrating on identifying bone defects visible in radiography to a more dynamic approach to also detect possible soft tissue injury, deteriorating hoof condition and age- or sport-related stress factors. The navicular bone is circled in this distal limb bone model at the University of Nottingham Vet School.

The landscape of treatment options for equine navicular syndrome is set to change this year, as the U.S. Food and Drug Agency (FDA) recently approved two drugs for use in the treatment of this complex lameness problem in the horse's foot. "Tildren" and "Osphos" are two specific medications that cleared the difficult hurdles of the FDA approval process in May 2014.